CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro

Ha-Yon Kim, Ji-Young Hwang, Seong-Woo Kim, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Deog-Yeon Jo

Cancer Research and Treatment. 2010;42(4):225-234. Published online 2010 December 31 DOI: https://doi.org/10.4143/crt.2010.42.4.225

The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma CellsIn Vitro

Ha-Yon Kim, Ji-Young Hwang, Seong-Woo Kim, Hyo-Jin Lee, Hwan-Jung Yun, Samyong Kim, Deog-Yeon Jo

Cancer Research and Treatment. 2010;42(4):225

Link1

Link2

The CXCR4 antagonist Plerixafor (AMD3100) promotes Ewing sarcoma cell survival and migration in Ewing sarcoma cells in vitro

U. Dirksen, P. Berning, C. Schaefer, J. Potratz

European Journal of Cancer. 2016;69:S50

Link1 Link2

The Dual Effect of CXCR4 Antagonist AMD3100 on the Recruitment of Endogenous Endothelial Precursor Cells and Outcome of Stroke

Yingfeng Xia, Qiaoyuan He, Chao Li, Ruyi Yuan, Nanliang Fu, Huiyao Xiang, Jing Mou, Ming Huang

. 2020;

Link1 Link2

Antitumor effect of CXCR4 antagonist AMD3100 on the tumorigenic cell line of BHP10-3 papillary thyroid cancer cells

Young Ho Jung, Doh Young Lee, Wonjae Cha, Bo Hae Kim, Myung-Whun Sung, Kwang Hyun Kim, Soon-Hyun Ahn

Head & Neck. 2016;38(10):1479-1486

Link1 Link2

The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation

S Tavor, M Eisenbach, J Jacob-Hirsch, T Golan, I Petit, K BenZion, S Kay, S Baron, N Amariglio, V Deutsch, E Naparstek, G Rechavi

Leukemia. 2008;22(12):2151-2158

Link1

Link2 Link3

T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure

Rieko Arakaki, Hirokazu Tamamura, Mariappan Premanathan, Kenji Kanbara, Sivasundaram Ramanan, Katsura Mochizuki, Masanori Baba, Nobutaka Fujii, Hideki Nakashima

Journal of Virology. 1999;73(2):1719-1723

Link1 Link2

The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells

D. Yoshida, K Koketshu, R. Nomura, A. Teramoto

Journal of Neuro-Oncology. 2010;100(1):51-64

Link1

Link2 Link3

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

R.J. Arceci

Yearbook of Oncology. 2010;2010:128-129

Link1 Link2

Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100

Halvard Bonig, Doreen Chudziak, Greg Priestley, Thalia Papayannopoulou

Experimental Hematology. 2009;37(3):402-415.e1

Link1 Link2

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers

Erik De Clercq

Pharmacology & Therapeutics. 2010;128(3):509-518

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.